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Worldwide, breast cancer in women remains to be the most common malignancy that in a considerable proportion shows the resis-
tance to genotoxic treatments and poor outcome. Chromosomal instability manifested as aneuploidy represents an integral cha-
racteristics of the malignant genotype not only because of the selection of mutated aneuploid sub-clones that stipulate the tumor 
progression, but also because of the reversible endopolyploidy of tumor cells that serves for the endless maintenance of therapy-
resistant tumor stem cells. Therefore, cytometric determination of DNA content in tissue samples for detecting malignancy, 
monitoring responses to therapy, and prognosing disease outcome needs to be revived. Both flow and image cytometry are most 
frequently used for generation of DNA content profiles (histograms), interpretation of which, however, may have some caveats. 
This review presents the major characterization criteria and analysis tools for breast cancer DNA histograms.
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INTRODUCTION
Breast cancer is among the most common malignan-
cies in women worldwide, and its manifestation consid-
erably varies based on cell proliferation state, karyotype 
and nuclear DNA content testifying aneuploidy. There 
is also the well-known cancer hallmark such as genome 
instability resulting in aneuploidy-linked elevated mu-
tagenicity [1, 2]. The latest research conducted on cell 
cultures and patient tumors as well showed that stem-
ness of tumor cells is tightly associated with polyploidi-
zation, the process that results in the numerical gain 
of the whole set of chromosomes [3–5]. This property 
stipulates the resistance to anti-cancer treatments and 
poor outcome [6]. It is supposed that the new treat-
ment strategies aimed to eradicate the highly evolvable 
polyploid cells would help to maintain tumors in a drug 
sensitive state [7]. In light of this newly emerged aspect 
in tumor cell biology, cytometric determination of DNA 
content in tissue samples “gets a second breath”, thus 
becoming a very important and demanding method not 
only for detecting malignancies, but also for assessing 
responses to therapy and disease outcome. Both flow 
and image cytometry are most frequently used for 
generation of DNA content profiles (histograms). Their 
interpretation, however, may have some caveats, and 
therefore needs to be univocal and accurate. The aim 
of this review is to present the major characterization 
criteria and analysis tools for breast cancer DNA histo-
grams that together can be used for gaining prognostic 
and treatment response information.
ANEUPLOIDY AND BREAST CANCER
Chromosomal instability (CIN) is the main reason 
of aneuploidy in cancer cells [8, 9]. Aneuploidy implies 
a condition in which the chromosome number is not 
exact multiple of the haploid karyotype. As a result 
of improper segregation of chromosomes during 
division of mother cell, two daughter cells become 
aneuploid. For example, one daughter cell has chro-
mosomal gain (2n+x), whereas another daughter cell 
has chromosomal loss (2n−x). However, in some other 
cases chromosomal gains and losses may not neces-
sarily be concordant. The fact that cells in the majo-
rity of aneuploid tumors have 40−60 chromosomes 
(while diploid cells have 46 chromosomes) indicates 
that the accumulation of chromosome imbalances 
generated by the sequential loss and gain of single 
chromosomes through CIN may be the most common 
pathway to aneuploidy [9]. Missegregation of chro-
mosomes can be due to defects in the kinetochore-
microtubule attachments and dynamics, centrosome 
number, spindle-assembly checkpoint, and chromo-
some cohesion [2]. The disruption of multiple genes 
and pathways is believed to play in the aforementioned 
defects [10].
Aneuploidy that was first proposed as a cause 
of cancer by D. Hansemann and Th. Boveri at the turn 
of 20th century was based on observations of multipo-
lar cell divisions and bipolar asymmetric segregation 
of chromosomes in large polyploid cells [11, 12]. With 
the beginning of the molecular biology era the most 
attention was switched to elementary genetic and 
molecular changes in cancer, while during the last two 
decades aneuploidy was again recognized as a main 
driver of cancer progression, and from some views, 
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aneuploidy together with CIN is considered as an origin 
of cancer [13–16].
Both structural and numerical chromosomal abnor-
malities, that can currently be detected by conventional 
karyotyping and other more advanced cytogenetic 
techniques such as ﬂ uorescence in situ hybridization, 
spectral karyotyping and array-based comparative 
genomic hybridization, are characteristic of cancer 
genomes. Contrary to structural chromosomal abnor-
malities, the role of numeric chromosomal abnormali-
ties (termed also as “whole-chromosome aneuploidy” 
or simply “aneuploidy”) in tumor development is much 
less well-understood largely because of difficulties 
to identify tumorigenesis related genes on aneuploid 
chromosomes [2, 17]. Although at least at low fre-
quency aneuploidy is likely to promote tumorigenesis, 
it is currently observed in most tumors including breast 
cancer (≈ 90% of solid tumors and 85% of hemato-
poietic malignancies) [16]. Understanding the role 
of aneuploidy specifically in these tumors is of great 
importance to uncover pathogenesis of disease and 
develop new strategies for treatment [2, 18, 19] and 
prognostication [20].
In breast cancer, the spindle-assembly checkpoint 
appears to be affected causing CIN [9]. Expression 
of MAD2 gene is essential to control this check-
point [21]. Mutations in BRCA1 and BRCA2 genes 
can also contribute to CIN. While the former gene 
is required for the proper spindle checkpoint func-
tion [22], the latter gene is required for proper cytoki-
nesis [23]. Of 200 breast cancer cases, there are ≈ 15% 
of tumors having cells with 46 chromosomes (these 
cells are not free of translocations, inversions, dele-
tions and/or additions), 70% of tumors having cells 
with > 46 but ≤ 68 chromosomes, and ≈ 15% of tumors 
having cells with ≥ 69 chromosomes [16]. Among 
those chromosomes that can be affected [24–27], 
chromosome 17 is affected most frequently (both 
numerical and structural abnormalities in this chromo-
some are common in breast cancer [27]). The majo-
rity of breast tumors (54%) have whole-chromosome 
17 aneuploidy, of which 14% are monosomic and 86% 
are polysomic [28]. Numerical aberrations of chromo-
some 17 (either gains or losses) are linked to breast 
cancer initiation and progression, and possibly to treat-
ment response [27]. Notably, this chromosome con-
tains such genes as HER2, BRCA1, P53, and TOP2A, 
whose alterations are of importance in breast cancer 
pathogenesis [27].
Polyploidization that occurs due to unscheduled 
whole-genome duplications has been proposed 
to constitute an important step in the development 
of cancer aneuploidy since it holds the probability 
to amortize consequences of chromosome damage 
or even loss [29, 30]. Transient and reversible polyploi-
dy works as a pro-survival mechanism after genotoxic 
treatment by activating pluripotency and self-renewal 
cassette (OCT4/SOX2/NANOG) characteristic for 
most aggressive tumors [6] and giving rise to resistant 
survivals after de-polyploidization [3,4].
In breast cancer cell lines as well as in breast can-
cer primary specimens, ionizing radiation can induce 
dose-dependent polyploidization together with mani-
festation of breast cancer stem cell phenotype in poly-
ploid cells [5]. Self-renewal activation in polyploid cells 
displays the property to overcome therapy-induced 
cell senescence [31]. Moreover, the development 
of rare polyploid cells in normal senescent fibroblasts 
correlates with self-renewal signaling, the fact that 
suggests that these polyploid cells can be potential 
cancer candidates [32]. Because of the definite role 
of polyploid cells in therapy resistance and tumor 
repopulation after therapy, they are currently consi-
dered as critical drug targets for tackling cancers [7]. 
Interestingly, tetraploidy is more frequent in BRCA2-
mutated than in sporadic breast carcinomas, the fact 
that prompts to propose that BRCA2 mutations can 
facilitate polyploidization through cytokinesis failure 
as well as formation of chromosome bridges [33].
BASIC DEFINITIONS IN DNA CYTOMETRY
DNA histogram is the distribution of the fre-
quency of integrated optical density (IOD) or inte-
grated fluorescence (IF) values obtained by cytometric 
measurements of cells stoichiometrically stained for 
DNA. In DNA histogram diploidy is shown by the po-
sition of the modal value of the peak corresponding 
to G0-/G1-phase cells having diploid chromosomal set 
2n (this position is usually expressed as 2c). In case 
if the modal value of the peak differs from that of nor-
mal diploid cells (< 2c or > 2c, excluding 4c), one 
could conclude that sample contains cells with aneu-
ploidy. The term “aneuploidy” also implies a biological 
phenomenon (concisely considered in the previous 
section). Appearance of additional peak(s) (4c, 8c, 
16c, etc.) corresponding to cells with geometrically 
doubled set of chromosomes is characteristic to poly-
ploidy. In case if DNA distribution in the examined 
sample cannot be differentiated from that of normal 
(resting, proliferating, or polyploidizing) cell popula-
tion, there could be euploidy. Diploid (2c) and tetra-
ploid (4c) tumors are often considered as euploid. DNA 
stemline is the G0-/G1-phase cell fraction of prolife-
rating cell population with a unique chromosomal 
outfit. In DNA histogram stemline shows a distinct 
peak (Xc) with a second doubling one (2Xc) [20].
TYPING OF DNA HISTOGRAMS 
FOR BREAST CANCER PROGNOSIS 
(Auer’s classification)
Based on the analysis of Feulgen method-stained 
tumor biopsy material, Auer et al. [34] first proposed 
classification of breast cancer DNA histograms. These 
histograms are empirically divided into 4 groups. 
The type I histogram is characterized by a single 
distinct modal DNA value in the diploid (or near-
diploid) region (2c) of normal cells with only a minor 
fraction of cells exhibiting higher DNA values (> 2c). 
The type II histogram has either a distinct peak 
in tetraploid (or near-tetraploid) region (4c) of nor-
mal cells or a couple of well-defined peaks in 2c and 
Experimental Oncology 36, 219–225, 2014 (December) 221
4c regions, although the presence of the minor peak 
corre sponding to octoploid cells (8c) is also pos-
sible (< 5%). There are no at all or there are few cells 
that have DNA amounts corresponding to the DNA 
synthesis phase of normal cells (< 5%). Although 
type III histogram like type II histogram often shows 
two peaks in 2c and 4c regions, it is similar to that 
of proliferating normal cell population with DNA values 
scattered between the normal 2c and 4c region. There 
is a sizable number (> 5%) of cells with DNA amounts 
similar to those of normal S-phase cells. Later, it has 
been recognized that this type of histogram is most 
difficult to delineate [35, 36]. The type IV histogram 
is characterized by the large fraction of aneuploid 
tumor cells with highly increased and scattered DNA 
values significantly exceeding the normal 4c region. 
There is a distinct correlation between the type of DNA 
distribution pattern of breast cancer and the survival 
time of the individual. Histograms of types III and IV are 
indicative of worst prognosis. Auer et al. [37] also 
demonstrated that metastases and primary tumors 
shared the same DNA histogram pattern. Thus, while 
tumors exhibiting DNA values within the limits of normal 
tissue correlate with favorable prognosis, tumors with 
increased and scattered DNA values are indicative 
of poor prognosis.
ADDITIONAL PARAMETERS FOR 
SUCCESSFUL EVALUATION OF BREAST 
CANCER DNA HISTOGRAMS
Opfermann et al. [36] noted that Auer’s classifica-
tion is limited in that “it did not take into account gen-
eral important biologic parameters which could alter 
the biologic behavior of cells” (assuming the necessity 
to estimate individual cells based on the phase of mitotic 
cycle, and cell population growth fraction). In this re-
gard, the authors proposed to introduce two additional 
parameters such as ploidy balance and proliferation 
index that can be derived by distributing breast can-
cer biopsy cells in 10 different ploidy intervals ranging 
from 2c to > 8c. This way of histograms classification 
is free of uncertainties related to the statements such 
as “near-diploid” or “near-tetraploid” used in the defi-
nition of Auer histogram patterns. The ploidy balance 
is simply calculated by subtraction of the percentage 
of aneuploid cells (2.5c, 3c, 3.5c, 5c, 6c, 7c, and > 8c) 
from the percentage of euploid cells (2c, 4c, and 8c). 
Accordingly, the difference can fluctuate from +100% 
(all cells are euploid) to −100% (all cells are aneuploid). 
Proliferation index is the percentage of cells between 
major and related peaks (regardless of the ploidy level 
of the major peak). Although these parameters de-
monstrate that aneuploidy and cell proliferation does 
correlate with tumor aggressiveness as derived from 
the “tumor aggressiveness triangle”, at least 15% 
of the patients failed to be correctly classified in terms 
of long vs. short survival time [36]. Therefore, additional 
parameters should be taken into consideration.
There is more precise approach based on calcu-
lation of DNA index (DI) which is defined as the ratio 
of the modal DNA value of the tumor cells to the modal 
DNA value of the internal control cells (2c). This pa-
rameter that was first introduced by Barlogie et al. 
[38, 39] is being actively used since the early 80th 
of the last century when the flow cytometry era 
started to bloom. Fernö et al. [40] proposed to cate-
gorize the ploidy of breast cancer cell populations 
based on DI distribution as follows: hypodiploid 
(DI < 0.95), diploid (DI = 0.95−1.04), near-hyperdiploid 
(DI = 1.05−1.14), hyperdiploid (DI = 1.15−1.91), tet-
raploid (DI = 1.92−2.04), hypertetraploid (DI ≥ 2.05), 
and multiploid (in case if DNA histogram has ≥ 2 peaks 
corresponding to aneuploid/polyploid cell population). 
This type of DI categorization compared with those 
proposed by other authors also includes the class 
of near-hyperdiploid tumors whose cells can yet 
be distinguished from diploid (2c) cells.
Determination of DI is often supplemented with de-
tection of cell proliferation level by measurements 
of S-phase fraction (SPF), which is expressed 
as a percentage of tumor cells in DNA synthesis phase 
of the cell-cycle. This parameter correlates with proli-
ferative activity of tumor cells. At present, quantifica-
tion of SPF is usually performed by means of special 
mathematical models in computer programs for cell-
cycle analysis. Notably, the earliest method that was 
actively used for SPF quantification is a planimetric 
method of Baisch et al. [41] assuming that the S-phase 
compartment constitutes a rectangle distribution be-
tween the modal values of G0/G1 and G2 peaks. Flow cy-
tometrically measured SPF correlates with the labeling 
index measured by autoradiography of tumor biopsies 
pulse-labeled with tritiated thymidine [42, 43].
SPF parameter appears to be prognostically very 
informative for some human cancers, including breast 
cancer [44, 45]. Starting from the middle of 80th 
of the last century, SPF became an object of exten-
sive exploration for delineating of its prognostic value 
in breast cancer. In one of the earliest works on this is-
sue, Hedley et al. [46] demonstrated that disease-free 
survival with SPF ≤ 10% was significantly longer than 
that with SPF > 10%, and the latter SPF value strongly 
correlated with high tumor grade and abnormal DI but 
weakly correlated with nodal, hormone (estrogen) 
receptor, and menopausal status. The fact that SPF 
values are significantly higher in aneuploid tumors than 
in diploid tumors is confirmed in other reports [47−51]. 
According to Clark et al. [48], SPF is highly predictive 
of di sease-free survival in patients with diploid tumors 
but does not provide additional prognostic informa-
tion for aneuploid cases. Sigurdsson et al. [49, 50] 
proposed to gain prognostic information by dividing 
the SPF into 3 prognostic categories: low (< 7.0%), 
intermediate (7.0−11.9%) and high (≥ 12%). These 
cate gories allow grouping the patients according 
to their level of risk. The risk of death or recurrence for 
diploid and non-diploid cases is up to 50% higher for 
the high S-phase category than for the intermediate 
category, and approximately 50% higher for the inter-
mediate category than for the low category [49]. In this 
222 Experimental Oncology 36, 219–225, 2014 (December)
situation, ploidy does not provide additional prognostic 
information with reference to any of S-phase catego-
ries. In spite of different techniques (e.g., whether 
the tissue is fresh, frozen, or paraffin-embedded, etc.) 
and cut-points (e.g., whether the SPF is di- or tri-
chotomized, etc.), correlations between SPF and other 
prognostic markers are relatively consistent across 
studies: higher SPF is generally associated with worse 
tumor grade, negative receptor status, larger tumors, 
and positive axillary nodes [52]. Moreover, higher 
SPF is generally associated with worse disease-free 
and overall survival in both univariate and multivariate 
analyses [52].
Since polyploidy can correlate with aggressiveness 
of cancer, the detection and analysis of polyploid cells 
in DNA histograms is of importance. Diploid (in cluding 
near-hyperdiploid) and hyperdiploid tumors are most 
common comprising about 45 and 36% of all breast 
cancer ploidy types, respectively [40].  Favo rable 
prognosis is more characteristic for diploid and near-
hyperdiploid cases (low-risk group) [40, 53, 54], 
though Fernö et al. [40] claim that prognosis for near-
hyperdiploid tumors that comprise only about 4.0% 
of all cases is even somewhat better than for diploid 
tumors. As for hypodiploid, hypertetraploid, and mul-
tiploid cases, all of them fall into the category of worse 
prognosis (high-risk group). Interestingly, in this group 
hypodiploid cases can be most aggressive [40, 55]. Hy-
perdiploid cases are probably to fall between low- and 
high-risk groups [40, 54–57]. However, there is some 
controversy regarding prognosis of tetraploid cases 
(≈ 5.0% of all cases). Some authors reported better 
prognosis for tetraploid cases [53, 56−58] than other 
authors did [40, 54]. Notably, Stål et al. [56] reported 
even a slightly longer survival in tetraploid cases than 
in diploid cases. Ewers et al. [59] found that the recur-
rence rate in early-stage disease was twice as low 
among patients with euploid (diploid and tetraploid) 
tumors as among patients with aneuploid tumors.
Although some investigators did report the lack 
of prognostic significance of DNA ploidy and/or SPF 
in breast cancer, those reports, however, are not 
numerous [52, 60]. In fact, the assignment of DI and 
SPF can be subjected to a number of various techni-
cal pitfalls that may take place starting with specimen 
preparation/processing and ending with instrument 
alignment and cell-cycle analysis [52, 61]. Also, tumors 
may not be usually consistent in their ploidy (there 
is variation in DNA content between different areas 
of the tumor) [62]. In this case, examination of tissue 
samples from several different areas of the tumor may 
be needed.
FLOW CYTOMETRY VERSUS IMAGE 
CYTOMETRY
Numerical and structural chromosomal abnor-
malities together can lead to DNA aneuploidy which 
is quantified cytometrically in a cell population. There 
is a variety of DNA staining methods using light-
absorbing or fluorescent stains that stoichiometrically 
bind to DNA, so DNA content can be measured based 
on IOD or IF values. As for staining of DNA with light-
absorbing dyes, the Feulgen reaction by using of Schiff 
reagent is still most popular, although this staining 
technique was developed almost a century ago [63]. 
As for fluorescence staining of DNA, there is a variety 
of nucleic acid fluorescent dyes, and some of them 
(e.g., Hoechst dyes, DAPI, and 7-AAD) selectively 
or preferably bind to DNA [64]. Both flow and image 
cytometry are frequently used for generation of DNA 
histograms of DNA-stained cell samples, although none 
of these techniques is free of disadvantages (Table).
Table. Major differences between flow and image cytometry that can af-
fect the quality of assessment of DNA content histograms obtained from 
cancer samples
Flow cytometry Image cytometry*
1. Few thousand cells or cell nu-
clei can be analyzed for a short time 
(≈ 1 min)
At least few dozen cell nuclei 
can be analyzed for a short time 
(≈ 1 min)
2. While performing analysis, mor-
phological assessment of cells 
is impossible
While performing analysis, morpho-
logical assessment of cells is pos-
sible
3. Quantification of S-phase cells 
is relatively precise
If DNA histogram peaks are 
too broad, additional staining 
of S-phase cells may be needed
4. More sensitive in detection 
of near-diploid aneuploidy
Less sensitive in detection of near-
diploid aneuploidy unless a larger 
cohort of nuclei is analyzed
5. Analysis requires cell suspension Samples can be prepared from cell 
suspension, tissue imprints or histo-
logical sections
Note: *image cytometry implies software-based analysis of IOD from digi-
talized images obtained by microscope equipped with CCD camera.
Nevertheless, flow cytometry is superior in terms 
of speedy acquiring a large cohort of cells or cell nuclei 
in sufficient numbers for precise statistical certainty. 
Because of this advantage, DNA histogram peaks look 
sharper (since coefficients of variation of the peaks 
become lower), and thus S-phase cells can be quanti-
fied with a special DNA content/cell-cycle analysis 
software. Several models have been proposed to es-
timate S-phase in overlapping populations that may 
take place in some tumors [43, 65]. Taking into account 
the aforementioned advantages, flow cytometry is gen-
erally well-described and widely used technique [66]. 
Contrary to flow cytometry, a few hundred cells are usu-
ally analyzed by image cytometry resulting in broader 
DNA histogram peaks (coefficients of variation of the 
peaks are relatively high). In this regard, the assessment 
of S-phase seems somewhat problematic, although 
there could be a good option for solving this situation 
by specific staining of those cells that proliferate (e.g., 
using antibodies to proliferation-associated antigens 
such as Ki-67 and PCNA [67, 68]). While performing 
analysis, flow cytometry compared with image cytom-
etry, however, is incapable of discriminating non-ma-
lignant cells of other types (lymphocytes, granulocytes, 
macrophages, and some stromal cells such as fibro-
blasts) unless they are specifically labeled. Using micro-
scope, an experienced operator can easi ly discriminate 
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these cells mainly based on size and shape of their nu-
clei and some nuclear texture features. Thereby, image 
cytometry-based generation of DNA histograms is less 
likely to be interfered by “contamination” with unwanted 
cells. As for detection of aneuploid cell populations, 
a combination of both techniques is superior to either 
of them alone [69]. However, none of these techniques 
can necessarily detect gains or losses of single intact 
chromosomes or deletions in individual chromosomes 
especially if a tissue sample contains a very small fraction 
of aneuploid cells. In general, there is a good correlation 
in DNA content analysis data between flow and image 
cytometry [69], although a thorough under standing and 
appreciation of the methodological problems associated 
with both techniques may be needed [70].
In 2001 there was the last consensus report on di-
agnostic DNA image cytometry proposed by the group 
of prominent European analytical cytologists [20]. 
With regard to identification of neoplasia and grading 
of tumor malignancy, this report contains several main 
clinically-oriented recommendations such as short 
description of DNA histogram (histogram type), 
interpretation of DNA histogram concerning the oc-
currence of DNA aneuploidy and/or the histogram 
type, prognostic interpretation of DNA histogram, 
and summarized morphologic/cytometric diagnosis. 
In that time when this report was written the usual 
precision of DNA image cytometric measurements 
should at least allow DNA stemlines to be identified 
as abnormal (or aneuploid), if they deviate more than 
10% from the diploid (2c) or tetraploid (4c) region, i.e., 
if they are outside 2c ± 0.2c or 4c ± 0.4c.
CONCLUDING REMARKS
Like two decades ago, DNA content profile re-
mains to be a subject of thorough examination to gain 
the information on prognosis of disease and response 
to treatment. For this purpose, combination of various 
characterization criteria and analysis tools for DNA 
histograms may be needed. Determination of consen-
sus values in interlaboratory comparisons is required.
Finally, it is worth to note the another principally dif-
ferent analytical approach of analysis of DNA-stained 
cancer specimens that currently shows promising data 
from diagnostic and prognostic points of view. This 
is nuclear texture measured by digital image analysis 
that allows detailing the phenotype by objective clas-
sifying of visual and sub-visual changes in nuclear 
chromatin [71]. Qualitative and quantitative changes 
in chromatin structure are of importance for under-
standing the neoplastic process as well as for identifying 
structural changes that may indicate functional altera-
tions [72]. Nuclear textural features have been proven 
to be successful in clinics for prognosis in several can-
cers including breast cancer [73]. However, the nuclear 
texture analysis should be performed on undistorted 
nuclei. For this purpose, monolayers of nuclei carefully 
isolated from the sections of formalin-fixed and paraffin-
embedded tissues are usually used [74].
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